Go Pro
→ They proved it worked in '76. Then buried it. (From Behind the Markets) (Ad)tc pixel Free PALI Stock Alerts

Palisade Bio (PALI) Financials

Palisade Bio logo
$1.89 -0.07 (-3.57%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$1.90 +0.01 (+0.26%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Palisade Bio

Annual Income Statements for Palisade Bio

This table shows Palisade Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -21 -16 -4.92 -8.35 -10 -27 -15 -12 0.00 0.00
Consolidated Net Income / (Loss)		 -21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Net Income / (Loss) Continuing Operations		 -21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Total Pre-Tax Income 		-21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Total Operating Income		 -19 -21 -13 -8.26 -8.63 -9.30 -42 -16 -13 -15 -18
Total Gross Profit		 0.01 0.02 0.26 0.26 0.02 0.00 0.00 0.00 0.25 0.00 0.00
Total Revenue		 0.01 0.02 0.26 0.26 0.02 0.00 0.00 0.00 0.25 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 19 21 14 8.52 8.65 9.30 42 16 13 15 18
Selling, General & Admin Expense		 6.53 7.50 5.47 4.56 4.59 6.20 9.31 8.76 6.20 5.80 7.86
Research & Development Expense		 13 13 8.10 3.96 4.06 3.10 33 6.55 6.89 9.06 10
Total Other Income / (Expense), net		 -1.75 -0.44 -2.36 3.34 0.28 -1.03 15 1.46 0.77 0.42 1.28
Interest Expense		 1.82 1.14 0.16 0.01 0.01 0.24 2.12 0.01 0.02 0.01 0.01
Other Income / (Expense), net		 -0.00 0.64 -2.27 3.27 0.22 -0.79 17 1.47 0.79 0.43 1.29
Basic Earnings per Share		 ($2.99) ($2.53) ($1.20) ($7.54) ($3.80) ($3.72) ($142.95) ($16.53) ($27.01) ($10.19) ($0.30)
Weighted Average Basic Shares Outstanding		 6.99M 8.35M 13.06M 653.22K 2.20M 2.77M 186.20K 880.31K 456.01K 1.42M 55.67M
Diluted Earnings per Share		 ($2.99) ($2.53) ($1.20) ($7.54) ($3.80) ($3.72) ($169.74) ($16.53) ($27.01) ($10.19) ($0.30)
Weighted Average Diluted Shares Outstanding		 6.99M 8.35M 13.06M 653.22K 2.20M 2.77M 186.96K 880.31K 456.01K 1.42M 55.67M
Weighted Average Basic & Diluted Shares Outstanding		 6.99M 8.35M 13.06M 653.22K 2.20M 13.87M 18.23M 4.50M 12.77M 4.40M 165.88M

Quarterly Income Statements for Palisade Bio

This table shows Palisade Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.61 -2.97 -3.53 -4.08 -3.49 11 -2.23 -2.78 -2.87 7.88 -9.60
Consolidated Net Income / (Loss)		 -3.60 -2.97 -3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60
Net Income / (Loss) Continuing Operations		 -3.60 -2.97 -3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60
Total Pre-Tax Income 		-3.60 -2.97 -3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60
Total Operating Income		 -3.78 -3.15 -3.67 -4.21 -3.59 -3.38 -2.31 -2.84 -2.92 -9.98 -11
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.78 3.15 3.67 4.21 3.59 3.38 2.31 2.84 2.92 9.98 11
Selling, General & Admin Expense		 1.67 1.56 1.46 1.58 1.46 1.30 1.36 1.17 1.53 3.81 4.35
Research & Development Expense		 2.10 1.37 2.21 2.63 2.14 2.08 0.95 1.68 1.39 6.17 6.40
Total Other Income / (Expense), net		 0.18 0.18 0.15 0.13 0.11 0.04 0.08 0.06 0.05 1.08 1.15
Other Income / (Expense), net		 0.19 0.19 0.15 0.13 0.11 0.04 0.08 0.06 0.06 1.08 1.15
Basic Earnings per Share		 ($7.38) ($6.52) ($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05)
Weighted Average Basic Shares Outstanding		 489.62K 456.01K 768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M
Diluted Earnings per Share		 ($7.38) ($6.52) ($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05)
Weighted Average Diluted Shares Outstanding		 489.62K 456.01K 768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M
Weighted Average Basic & Diluted Shares Outstanding		 9.22M 12.77M 937.56K 1.18M 1.33M 4.40M 4.80M 9.12M 149.00M 165.88M 173.58M

Annual Cash Flow Statements for Palisade Bio

This table details how cash moves in and out of Palisade Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -7.80 10 -8.52 -0.89 -0.67 -2.88 9.78 1.89 0.05 -2.61 124
Net Cash From Operating Activities		 -19 -16 -13 -7.69 -7.26 -4.77 -15 -13 -11 -12 -11
Net Cash From Continuing Operating Activities		 -19 -16 -13 -7.69 -7.26 -4.77 -15 -13 -11 -12 -11
Net Income / (Loss) Continuing Operations		 -21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Consolidated Net Income / (Loss)		 -21 -21 -16 -4.92 -8.35 -10 -27 -14 -12 -14 -17
Depreciation Expense		 0.35 0.34 0.29 0.19 0.14 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 2.95 3.26 4.05 -2.62 0.78 3.16 17 -0.27 0.77 0.73 4.26
Changes in Operating Assets and Liabilities, net		 -2.20 1.51 -2.15 -0.33 0.17 2.39 -4.78 1.17 0.40 1.51 1.67
Net Cash From Investing Activities		 7.25 2.36 -0.09 5.00 0.00 -0.01 -0.05 -0.01 -0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 7.25 2.36 -0.09 5.00 0.00 -0.01 -0.05 -0.01 -0.00 0.00 0.00
Purchase of Property, Plant & Equipment		 -0.18 -0.10 -0.01 - - -0.01 0.00 -0.01 -0.00 0.00 0.00
Net Cash From Financing Activities		 3.89 24 4.99 1.81 6.59 1.89 25 15 11 9.58 134
Net Cash From Continuing Financing Activities		 3.89 24 4.99 1.81 6.59 1.89 25 15 11 9.58 134
Repayment of Debt		 -1.27 -4.69 -4.09 -0.36 -0.38 -0.11 -1.58 -0.79 -0.39 -0.77 -0.82
Repurchase of Common Equity		 -0.05 - - - - 0.00 -0.07 -0.63 -0.62 -0.58 -0.62
Issuance of Common Equity		 - - - - 6.55 1.18 5.31 14 9.44 8.45 128
Other Financing Activities, net		 -0.80 - - 0.00 0.00 - - 2.27 2.76 2.48 7.64
Cash Interest Paid		 0.95 0.99 0.12 0.01 0.01 0.06 0.06 0.01 0.01 0.01 0.01

Quarterly Cash Flow Statements for Palisade Bio

This table details how cash moves in and out of Palisade Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.09 -2.88 -1.16 0.08 -3.31 1.78 -2.59 -1.81 -0.19 128 -0.76
Net Cash From Operating Activities		 -2.66 -2.75 -3.18 -3.50 -3.13 -2.38 -2.33 -1.82 -3.55 -3.14 -3.89
Net Cash From Continuing Operating Activities		 -2.66 -2.75 -3.18 -3.50 -3.13 -2.38 -2.33 -1.82 -3.55 -3.14 -3.89
Net Income / (Loss) Continuing Operations		 -3.60 -2.97 -3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60
Consolidated Net Income / (Loss)		 -3.60 -2.97 -3.53 -4.08 -3.49 -3.34 -2.23 -2.78 -2.87 -8.90 -9.60
Depreciation Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.41 0.18 0.12 0.44 -0.02 0.19 0.10 0.10 0.42 3.64 4.30
Changes in Operating Assets and Liabilities, net		 0.52 0.05 0.22 0.14 0.37 0.77 -0.20 0.87 -1.11 2.11 1.41
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 1.57 -0.13 2.02 3.58 -0.18 4.16 -0.26 0.00 3.36 131 3.13
Net Cash From Continuing Financing Activities		 1.57 -0.13 2.02 3.58 -0.18 4.16 -0.26 0.00 3.36 131 3.13
Repayment of Debt		 -0.15 -0.10 -0.48 -0.02 -0.11 -0.16 -0.08 - -0.55 -0.19 -0.07
Repurchase of Common Equity		 -0.02 -0.05 0.00 -0.39 -0.07 -0.12 -0.18 - - -0.44 -0.05
Issuance of Common Equity		 1.74 0.02 - - - 4.44 0.00 - - 128 3.25
Cash Interest Paid		 0.01 0.00 0.00 - 0.01 0.01 0.00 - 0.00 0.01 0.00

Annual Balance Sheets for Palisade Bio

This table presents Palisade Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 23 14 7.68 6.58 3.02 13 16 14 11 134
Total Current Assets		 13 21 12 6.51 5.65 0.90 12 15 13 10 134
Cash & Equivalents		 4.72 15 6.67 5.79 5.11 0.71 10 12 12 9.82 133
Prepaid Expenses		 1.16 0.65 0.40 0.36 0.51 0.12 1.01 2.35 0.90 0.67 0.84
Plant, Property, & Equipment, net		 0.34 0.27 0.17 0.09 0.04 0.01 0.00 0.01 0.01 0.00 0.00
Total Noncurrent Assets		 1.18 1.43 1.26 1.09 0.90 2.12 1.00 1.02 0.71 0.38 0.12
Other Noncurrent Operating Assets		 0.07 0.02 0.01 0.02 0.23 2.12 1.00 1.02 0.71 0.38 0.12
Total Liabilities & Shareholders' Equity		 15 23 14 7.68 6.58 3.02 13 16 14 11 134
Total Liabilities		 9.98 11 5.37 1.63 1.46 10 5.15 3.28 2.74 3.39 4.96
Total Current Liabilities		 6.43 7.33 1.51 1.05 1.22 8.08 2.50 3.01 2.59 3.24 4.64
Short-Term Debt		 4.55 3.71 - - - 0.58 - 0.09 0.16 0.08 0.07
Accounts Payable		 1.46 2.34 0.88 0.83 0.82 2.54 1.32 1.76 0.70 1.11 0.77
Accrued Expenses		 0.16 0.85 0.42 0.00 0.14 2.74 0.46 0.57 0.83 1.24 2.19
Current Employee Benefit Liabilities		 - - - - - 1.59 0.51 0.49 0.78 0.72 1.30
Other Current Liabilities		 0.26 0.43 0.22 0.22 0.26 0.64 0.20 0.11 0.12 0.09 0.31
Total Noncurrent Liabilities		 3.56 3.94 3.85 0.58 0.23 2.04 2.65 0.27 0.15 0.15 0.33
Other Noncurrent Operating Liabilities		 0.00 3.92 3.85 0.58 0.23 1.94 2.65 0.27 0.15 0.15 0.33
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4.97 11 8.52 6.05 5.13 -17 7.37 12 11 7.49 129
Total Preferred & Common Equity		 4.97 11 8.52 6.05 5.13 -17 7.37 12 11 7.49 129
Preferred Stock		 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4.97 11 8.51 6.04 5.12 -17 7.36 12 11 7.49 129
Common Stock		 177 204 217 220 227 51 102 122 133 143 282
Retained Earnings		 -172 -193 -209 -214 -222 -68 -95 -109 -122 -136 -153

Quarterly Balance Sheets for Palisade Bio

This table presents Palisade Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 17 13 13 9.34 8.19 6.67 6.97 133
Total Current Assets		 16 12 12 8.87 7.89 6.45 6.83 133
Cash & Equivalents		 15 11 11 8.04 7.23 5.42 5.23 133
Prepaid Expenses		 0.95 0.74 0.96 0.83 0.66 1.03 1.60 0.62
Plant, Property, & Equipment, net		 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.79 0.63 0.56 0.46 0.30 0.22 0.15 0.07
Other Noncurrent Operating Assets		 0.79 0.63 0.56 0.46 0.30 0.22 0.15 0.07
Total Liabilities & Shareholders' Equity		 17 13 13 9.34 8.19 6.67 6.97 133
Total Liabilities		 2.99 2.59 2.92 2.73 2.86 4.05 3.76 5.95
Total Current Liabilities		 2.65 2.47 2.84 2.68 2.78 3.97 3.48 5.62
Short-Term Debt		 0.26 0.00 0.35 0.24 0.00 0.31 0.21 0.00
Accounts Payable		 0.95 0.46 0.51 0.37 0.75 1.37 1.43 2.70
Accrued Expenses		 0.79 1.67 1.56 1.51 1.86 2.07 1.22 2.80
Current Employee Benefit Liabilities		 0.53 0.21 0.29 0.45 0.12 0.19 0.62 0.12
Other Current Liabilities		 0.12 0.13 0.13 0.12 0.06 0.02 0.00 0.00
Total Noncurrent Liabilities		 0.34 0.12 0.09 0.05 0.08 0.08 0.28 0.33
Other Noncurrent Operating Liabilities		 0.34 0.12 0.09 0.05 0.08 0.08 0.28 0.33
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 10 9.95 6.61 5.33 2.62 3.21 127
Total Preferred & Common Equity		 14 10 9.95 6.61 5.33 2.62 3.21 127
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 14 10 9.95 6.61 5.33 2.62 3.21 127
Common Stock		 133 135 139 139 144 144 147 290
Retained Earnings		 -119 -125 -129 -133 -138 -141 -144 -162

Annual Metrics And Ratios for Palisade Bio

This table displays calculated financial ratios and metrics derived from Palisade Bio's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 91,786,290.00 114,859,175.00 15,146,027.00 18,205,060.00 3,866,457.00 17,295,703.00 13,574,049.00 77,080,169.00 9,217,129.00 1,329,516.00 149,003,210.00
DEI Adjusted Shares Outstanding		 20,397.00 25,524.00 3,366.00 4,046.00 859.00 3,843.00 18,099.00 102,774.00 614,475.00 1,329,516.00 149,003,210.00
DEI Earnings Per Adjusted Shares Outstanding		 -1,024.85 -825.68 -4,654.18 -1,217.16 -9,722.53 -2,685.92 -1,470.58 -141.55 -20.04 0.00 0.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -44.69% 55.96% 1,500.39% 0.00% -94.08% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00%
EBITDA Growth		 7.76% -7.61% 21.13% 68.45% -72.06% -21.98% -142.91% 41.85% 13.78% -17.44% -16.26%
EBIT Growth		 7.14% -4.36% 22.08% 67.96% -68.54% -19.93% -142.86% 41.84% 13.77% -17.43% -16.26%
NOPAT Growth		 -9.87% -7.73% 35.52% 37.93% -4.51% -7.71% -350.19% 62.44% 16.86% -13.69% -21.52%
Net Income Growth		 7.62% -0.82% 25.66% 68.56% -69.59% -23.59% -157.86% 46.42% 13.74% -17.38% -16.23%
EPS Growth		 7.62% -0.82% 52.57% 68.56% 49.60% -23.59% -157.86% 90.26% 13.74% 62.27% 97.06%
Operating Cash Flow Growth		 -61.72% 17.51% 14.09% 42.66% 5.68% 34.29% -209.84% 9.56% 16.67% -9.52% 11.04%
Free Cash Flow Firm Growth		 -26.18% 44.62% -33.37% 18.55% 37.07% 111.11% -5,278.64% 57.01% 44.10% -13.87% -20.18%
Invested Capital Growth		 179.53% -715.39% 38.56% 108.31% -95.78% -64,563.71% 56.16% 105.88% -622.28% -133.92% -75.00%
Revenue Q/Q Growth		 -17.21% 62.46% 1,500.39% -49.02% 0.00% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 1.69% -5.80% 10.68% 38.16% -26.00% 23.92% -0.31% -50.73% 5.74% -2.66% -49.55%
EBIT Q/Q Growth		 1.54% -4.60% 10.83% 37.50% -25.53% 24.08% -0.31% -50.75% 5.75% -2.66% -49.54%
NOPAT Q/Q Growth		 1.49% -6.73% 20.27% 5.32% -3.95% -19.50% -0.91% 1.12% 5.04% -1.56% -57.60%
Net Income Q/Q Growth		 3.41% -3.09% 11.72% 37.82% -25.88% 22.43% 0.47% -50.63% 5.74% -2.65% -49.48%
EPS Q/Q Growth		 3.41% -3.09% 4.76% 37.82% -70.40% 22.43% 0.47% -70.06% 5.74% -8.75% 80.00%
Operating Cash Flow Q/Q Growth		 -2.26% -1.17% 11.80% 7.55% -5.69% 9.51% -11.36% -1.91% 4.79% 2.91% -7.57%
Free Cash Flow Firm Q/Q Growth		 -10.58% 5.52% 18.13% -25.13% 14.89% 109.74% -81.61% 27.40% 18.88% 9.00% -47.76%
Invested Capital Q/Q Growth		 2,116.54% -11.47% -26.54% 121.03% 104.31% -895.97% 68.05% 115.30% 1.03% -87.80% -118.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -172,230.53% -118,842.48% -5,857.00% -1,847.89% -53,700.16% 0.00% 0.00% 0.00% -4,912.40% 0.00% 0.00%
Operating Margin		 -183,896.78% -127,027.23% -5,118.12% -3,176.71% -56,071.81% 0.00% 0.00% 0.00% -5,228.00% 0.00% 0.00%
EBIT Margin		 -183,903.66% -123,058.90% -5,991.23% -1,919.35% -54,634.68% 0.00% 0.00% 0.00% -4,914.00% 0.00% 0.00%
Profit (Net Income) Margin		 -200,671.03% -129,721.85% -6,025.38% -1,894.08% -54,252.64% 0.00% 0.00% 0.00% -4,920.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.11% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 109.12% 105.41% 100.57% 98.58% 99.30% 102.33% 108.65% 100.09% 100.12% 100.08% 100.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -4,418.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -4,375.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 4,268.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -184.28% -258.62% -157.88% -67.62% -149.46% 1,046.32% -20,012.03% -143.72% -103.40% -153.55% -24.52%
Cash Return on Invested Capital (CROIC)		 -1,831.15% 0.00% 0.00% -3,506.32% -4,234.36% 0.00% 0.00% -7,781.90% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -85.54% -106.47% -85.38% -46.27% -117.89% 0.00% 0.00% 0.00% -82.41% 0.00% 0.00%
Return on Assets (ROA)		 -93.33% -112.24% -85.87% -45.66% -117.07% 0.00% 0.00% 0.00% -82.51% 0.00% 0.00%
Return on Common Equity (ROCE)		 -184.28% -258.46% -157.72% -67.53% -149.30% 6,087.00% 695,079.50% -143.69% -103.38% -153.52% -24.52%
Return on Equity Simple (ROE_SIMPLE)		 -420.83% -185.99% -183.98% -81.40% -162.93% 62.17% -361.38% -114.27% -108.72% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -14 -9.31 -5.78 -6.04 -6.51 -29 -11 -9.15 -10 -13
NOPAT Margin		 -128,727.75% -88,919.06% -3,582.68% -2,223.70% -39,250.27% 0.00% 0.00% 0.00% -3,659.60% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -65.45% -64.35% -45.13% 9.82% -42.37% -147.95% 50.91% -28.57% -25.65% -36.67% -5.79%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -79.76% -137.38% -9.76%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 62,682.80% 46,147.99% 2,104.23% 1,753.56% 29,788.48% 0.00% 0.00% 0.00% 2,480.80% 0.00% 0.00%
R&D to Revenue		 121,313.99% 80,979.24% 3,113.88% 1,523.15% 26,383.33% 0.00% 0.00% 0.00% 2,757.20% 0.00% 0.00%
Operating Expenses to Revenue		 183,996.78% 127,127.23% 5,218.12% 3,276.71% 56,171.81% 0.00% 0.00% 0.00% 5,328.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -19 -20 -16 -4.99 -8.41 -10 -24 -14 -12 -14 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -19 -15 -4.80 -8.27 -10 -24 -14 -12 -14 -17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4,948.46 721.21 61.26 18.88 0.75 0.00 2.40 0.64 0.48 0.29 2.71
Price to Tangible Book Value (P/TBV)		 6,361.69 790.33 68.36 21.61 0.86 0.00 2.40 0.64 0.48 0.29 2.71
Price to Revenue (P/Rev)		 2,359,639.86 502,563.68 2,003.94 438.46 248.65 0.00 0.00 0.00 21.75 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 29,423.10 0.00 0.00 412.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2,359,243.20 501,550.45 1,959.08 416.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 38.38 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.63 0.33 0.00 0.00 0.00 -0.09 0.00 0.01 0.01 0.01 0.00
Long-Term Debt to Equity		 0.72 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.26 -1.42 -1.20 -0.98 2.61 -39.61 -1.15 -1.03 -1.17 -1.05
Leverage Ratio		 1.97 2.30 1.84 1.48 1.28 -4.87 58.39 1.42 1.25 1.33 1.06
Compound Leverage Factor		 2.15 2.43 1.85 1.46 1.27 -4.98 63.44 1.43 1.25 1.33 1.06
Debt to Total Capital		 61.99% 24.74% 0.02% 0.00% 0.00% -10.46% 0.00% 0.70% 1.38% 1.04% 0.05%
Short-Term Debt to Total Capital		 34.78% 24.62% 0.00% 0.00% 0.00% -8.99% 0.00% 0.70% 1.38% 1.04% 0.05%
Long-Term Debt to Total Capital		 27.22% 0.12% 0.02% 0.00% 0.00% -1.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.07% 0.12% 0.17% 0.04% 0.00% 0.03% 0.02% 0.02% 0.03% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -147.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 38.01% 75.20% 99.86% 99.83% 99.96% 258.32% 99.97% 99.28% 98.61% 98.93% 99.94%
Debt to EBITDA		 -0.45 -0.19 0.00 0.00 0.00 -0.07 0.00 -0.01 -0.01 -0.01 0.00
Net Debt to EBITDA		 0.23 0.85 0.77 0.00 0.00 0.00 0.00 0.86 1.00 0.68 7.95
Long-Term Debt to EBITDA		 -0.20 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.60 -0.26 0.00 0.00 0.00 -0.10 0.00 -0.01 -0.02 -0.01 -0.01
Net Debt to NOPAT		 0.31 1.14 1.25 0.00 0.00 0.01 0.00 1.12 1.34 0.94 10.55
Long-Term Debt to NOPAT		 -0.27 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1,457.67 420.39 34.44 1.66 -49.03 -44.53 -14.13 -10.32 -12.86 -20.68 41.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.06% 0.10% 0.14% 0.11% -481.75% 3,573.31% 0.02% 0.02% 0.02% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.09 2.85 8.22 6.19 4.61 0.11 4.61 4.89 5.15 3.24 28.95
Quick Ratio		 1.91 2.76 7.95 5.85 4.19 0.10 4.20 4.11 4.81 3.03 28.77
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -8.47 -11 -9.20 -5.79 0.64 -33 -14 -8.00 -9.11 -11
Operating Cash Flow to CapEx		 -10,740.03% -15,920.51% -117,675.31% 0.00% 0.00% -79,466.67% 0.00% -133,600.00% -278,325.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -8.42 -7.42 -71.02 -1,195.37 -649.20 2.74 -15.72 -1,101.44 -533.60 -759.53 -1,095.32
Operating Cash Flow to Interest Expense		 -10.42 -13.68 -84.34 -999.28 -813.42 -20.29 -6.97 -1,027.69 -742.20 -1,016.08 -1,084.70
Operating Cash Flow Less CapEx to Interest Expense		 -10.52 -13.77 -84.42 -999.05 -813.42 -20.31 -6.97 -1,028.46 -742.47 -1,016.08 -1,084.70
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.02 0.00 0.00
Accounts Receivable Turnover		 0.08 0.32 1.20 0.71 0.08 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.03 0.05 1.18 1.98 0.23 0.00 0.00 0.00 25.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 4,604.81 1,133.33 305.45 512.11 4,493.85 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 4,604.81 1,133.33 305.45 512.11 4,493.85 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.84 -5.14 -3.16 0.26 0.01 -7.14 -3.13 0.18 -0.96 -2.25 -3.93
Invested Capital Turnover		 -0.10 -0.01 -0.06 -0.18 0.11 0.00 0.00 0.00 -0.64 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.89 -5.98 1.98 3.42 -0.25 -7.15 4.01 3.31 -1.15 -1.29 -1.69
Enterprise Value (EV)		 24,576 8,148 509 108 -1.29 25 7.15 -4.28 -6.83 -7.55 217
Market Capitalization		 24,580 8,165 521 114 3.83 15 18 8.02 5.44 2.19 350
Book Value per Share		 $0.05 $0.10 $0.56 $0.33 $1.33 ($0.96) $0.54 $0.16 $1.23 $5.63 $0.87
Tangible Book Value per Share		 $0.04 $0.09 $0.50 $0.29 $1.15 ($0.96) $0.54 $0.16 $1.23 $5.63 $0.87
Total Capital		 13 15 8.52 6.05 5.13 -6.43 7.37 13 11 7.57 129
Total Debt		 8.10 3.72 0.00 0.00 0.00 0.67 0.00 0.09 0.16 0.08 0.07
Total Long-Term Debt		 3.56 0.02 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.13 -16 -12 -5.79 -5.11 -0.04 -10 -12 -12 -9.74 -133
Capital Expenditures (CapEx)		 0.18 0.10 0.01 -0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.68 -2.92 -0.74 -0.33 -0.69 -7.32 -1.49 -0.57 -1.53 -2.48 -3.73
Debt-free Net Working Capital (DFNWC)		 12 17 11 5.46 4.42 -6.61 9.01 12 11 7.34 130
Net Working Capital (NWC)		 7.01 14 11 5.46 4.42 -7.19 9.01 12 11 7.26 130
Net Nonoperating Expense (NNE)		 7.49 6.63 6.35 -0.86 2.31 3.81 -2.68 3.26 3.15 4.04 4.14
Net Nonoperating Obligations (NNO)		 -4.13 -16 -12 -5.79 -5.11 -0.04 -10 -12 -12 -9.74 -133
Total Depreciation and Amortization (D&A)		 1.22 0.68 0.35 0.19 0.14 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -6,558.45% -17,960.54% -284.89% -126.88% -4,500.41% 0.00% 0.00% 0.00% -612.80% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 110,884.05% 106,346.66% 4,205.47% 2,098.93% 28,726.28% 0.00% 0.00% 0.00% 4,360.00% 0.00% 0.00%
Net Working Capital to Revenue		 67,251.72% 83,536.21% 4,205.47% 2,098.93% 28,726.28% 0.00% 0.00% 0.00% 4,296.80% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1,035.00) ($11,385.00) ($5,400.00) ($1,440.00) ($17,100.00) ($5,265.00) ($2,145.00) ($247.95) ($27.00) ($10.19) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 20.45K 2.46K 3.37K 4.05K 2.10K 3.84K 12.41K 58.69K 456.01K 1.42M 55.67M
Adjusted Diluted Earnings per Share		 ($1,035.00) ($11,385.00) ($5,400.00) ($1,440.00) ($17,100.00) ($5,265.00) ($2,542.50) ($247.95) ($27.00) ($10.19) ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 20.45K 2.46K 3.37K 4.05K 2.10K 3.84K 12.46K 58.69K 456.01K 1.42M 55.67M
Adjusted Basic & Diluted Earnings per Share		 ($1,035.00) ($11,385.00) ($5,400.00) ($1,440.00) ($17,100.00) ($5,265.00) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 20.19K 1.86K 2.90K 3.37K 488.00 3.08K 24.31K 300.27K 851.40K 4.40M 165.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -14 -9.31 -5.78 -6.04 -6.51 -29 -11 -8.99 -10 -13
Normalized NOPAT Margin		 -128,727.75% -88,919.06% -3,582.68% -2,223.70% -39,250.27% 0.00% 0.00% 0.00% -3,596.60% 0.00% 0.00%
Pre Tax Income Margin		 -200,671.03% -129,721.85% -6,025.38% -1,892.01% -54,252.64% 0.00% 0.00% 0.00% -4,920.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10.55 -17.52 -97.93 -648.26 -942.88 -42.92 -11.56 -1,095.92 -819.00 -1,202.17 -1,677.10
NOPAT to Interest Expense		 -7.38 -12.66 -58.56 -751.05 -677.38 -27.69 -13.83 -846.52 -609.93 -866.78 -1,263.92
EBIT Less CapEx to Interest Expense		 -10.65 -17.60 -98.00 -648.04 -942.88 -42.95 -11.56 -1,096.69 -819.27 -1,202.17 -1,677.10
NOPAT Less CapEx to Interest Expense		 -7.48 -12.74 -58.63 -750.83 -677.38 -27.72 -13.83 -847.28 -610.20 -866.78 -1,263.92
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.22% 0.00% 0.00% 0.00% 0.00% 0.00% -0.25% -4.40% -5.02% -3.99% -3.68%

Quarterly Metrics And Ratios for Palisade Bio

This table displays calculated financial ratios and metrics derived from Palisade Bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 6,855,744.00 9,217,129.00 12,771,015.00 937,562.00 1,184,487.00 1,329,516.00 4,396,646.00 4,795,646.00 9,119,152.00 149,003,210.00 165,884,817.00
DEI Adjusted Shares Outstanding		 457,050.00 614,475.00 851,401.00 937,562.00 1,184,487.00 1,329,516.00 4,396,646.00 4,795,646.00 9,119,152.00 149,003,210.00 165,884,817.00
DEI Earnings Per Adjusted Shares Outstanding		 -7.90 -4.84 -4.14 -4.35 -2.94 8.34 -0.51 -0.58 -0.31 0.05 -0.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 10.03% 20.13% -50.71% -20.34% 2.98% -12.61% 36.79% 31.79% 17.76% -166.30% -330.83%
EBIT Growth		 10.01% 20.18% -50.68% -20.30% 2.98% -12.61% 36.78% 31.78% 17.75% -166.30% -330.64%
NOPAT Growth		 14.39% 18.04% -45.24% -16.68% 4.90% -7.23% 37.11% 32.49% 18.68% -195.12% -365.28%
Net Income Growth		 9.90% 20.13% -50.73% -20.25% 3.03% -12.55% 36.77% 31.76% 17.75% -166.12% -330.49%
EPS Growth		 9.90% 20.13% -50.73% 58.13% 68.56% 220.09% 89.76% 82.53% 83.62% -98.21% 89.36%
Operating Cash Flow Growth		 12.43% 16.94% 9.81% -59.12% -17.69% 13.29% 26.64% 48.07% -13.41% -32.05% -66.74%
Free Cash Flow Firm Growth		 75.38% 82.31% 77.68% 16.35% 20.42% -1.66% -2.30% 73.04% 37.16% -390.62% -346.95%
Invested Capital Growth		 19.29% -622.28% -369.33% -449.48% -23.28% -133.92% -56.68% -135.36% -50.71% -75.00% -177.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -5.87% 17.28% -18.81% -15.66% 14.64% 3.99% 33.31% -24.82% -2.91% -210.87% -7.89%
EBIT Q/Q Growth		 -5.84% 17.31% -18.84% -15.66% 14.64% 4.02% 33.28% -24.81% -2.91% -210.76% -7.89%
NOPAT Q/Q Growth		 -4.68% 16.52% -16.46% -14.65% 14.68% 5.87% 31.70% -23.07% -2.78% -241.58% -7.68%
Net Income Q/Q Growth		 -5.98% 17.38% -18.71% -15.68% 14.53% 4.10% 33.31% -24.84% -3.02% -210.29% -7.88%
EPS Q/Q Growth		 -5.98% 17.38% -18.71% 27.67% 30.12% 437.50% -106.00% -23.40% 34.48% 136.84% -135.71%
Operating Cash Flow Q/Q Growth		 -21.06% -3.16% -15.80% -10.03% 10.46% 24.00% 2.02% 22.12% -95.54% 11.51% -23.73%
Free Cash Flow Firm Q/Q Growth		 -15.42% 63.05% 14.46% -129.31% -9.80% 52.80% 13.92% 39.56% -155.90% -268.51% 21.58%
Invested Capital Q/Q Growth		 -405.73% 1.03% -26.12% 12.95% -13.46% -87.80% 15.52% -30.75% 27.35% -118.07% -33.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.04% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.22% 100.13% 100.03% 100.05% 100.17% 100.09% 100.00% 100.07% 100.17% 100.02% 100.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -98.44% -103.40% -113.28% -110.09% -135.96% -153.55% -170.72% -188.48% -228.64% -24.52% -36.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -98.42% -103.38% -113.26% -110.08% -135.93% -153.52% -170.67% -188.42% -228.54% -24.52% -36.40%
Return on Equity Simple (ROE_SIMPLE)		 -92.66% 0.00% -134.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.64 -2.21 -2.57 -2.95 -2.52 -2.37 -1.62 -1.99 -2.05 -6.99 -7.52
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.63% -6.21% -7.78% -8.39% -8.50% -8.87% -6.62% -9.86% -12.83% -2.67% -2.97%
Return On Investment Capital (ROIC_SIMPLE)		 - -19.25% -25.55% -28.62% -36.75% -31.27% -30.33% -67.83% -59.75% -5.40% -5.91%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.59 -2.97 -3.53 -4.08 -3.48 -3.34 -2.23 -2.78 -2.86 -8.90 -9.60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.59 -2.97 -3.53 -4.08 -3.48 -3.34 -2.23 -2.78 -2.86 -8.90 -9.60
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.28 0.48 0.51 0.42 0.64 0.29 0.56 1.25 2.44 2.71 2.28
Price to Tangible Book Value (P/TBV)		 0.28 0.48 0.51 0.42 0.64 0.29 0.56 1.25 2.44 2.71 2.28
Price to Revenue (P/Rev)		 15.96 21.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 2.31 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 43.33% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.01 0.00 0.04 0.04 0.01 0.00 0.12 0.07 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.03 -1.03 -1.05 -1.10 -1.17 -1.20 -1.28 -1.31 -1.05 -1.05
Leverage Ratio		 1.26 1.25 1.17 1.21 1.28 1.33 1.35 1.55 1.66 1.06 1.07
Compound Leverage Factor		 1.26 1.25 1.17 1.21 1.28 1.33 1.35 1.56 1.66 1.06 1.07
Debt to Total Capital		 1.81% 1.38% 0.00% 3.39% 3.43% 1.04% 0.00% 10.70% 6.16% 0.05% 0.00%
Short-Term Debt to Total Capital		 1.81% 1.38% 0.00% 3.39% 3.43% 1.04% 0.00% 10.70% 6.16% 0.05% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.01% 0.02% 0.02% 0.02% 0.03% 0.03% 0.04% 0.07% 0.06% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.18% 98.61% 99.98% 96.59% 96.54% 98.93% 99.96% 89.23% 93.78% 99.94% 100.00%
Debt to EBITDA		 -0.02 -0.01 0.00 -0.02 -0.02 -0.01 0.00 -0.03 -0.02 0.00 0.00
Net Debt to EBITDA		 1.16 1.00 0.00 0.78 0.56 0.68 0.00 0.43 0.45 7.95 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 -0.02 0.00 -0.03 -0.02 -0.01 0.00 -0.04 -0.03 -0.01 0.00
Net Debt to NOPAT		 1.56 1.34 0.00 1.06 0.76 0.94 0.00 0.60 0.63 10.55 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -8.64 -10.68 -12.67 -13.34 -19.39 -17.32 -23.14 -30.05 -28.40 41.67 28.47
Noncontrolling Interest Sharing Ratio		 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.03% 0.03% 0.04% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.14 5.15 4.87 4.34 3.31 3.24 2.84 1.62 1.96 28.95 23.71
Quick Ratio		 5.78 4.81 4.57 4.00 3.00 3.03 2.60 1.36 1.50 28.77 23.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.88 -1.06 -0.91 -2.08 -2.29 -1.08 -0.93 -0.56 -1.44 -5.30 -4.16
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -359.58 -265.70 -909.10 -1,042.35 -381.52 -360.13 0.00 -281.05 -287.68 -2,650.35 0.00
Operating Cash Flow to Interest Expense		 -332.75 -686.50 -3,180.00 -1,749.50 -522.17 -793.67 0.00 -908.50 -710.60 -1,572.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -332.75 -686.50 -3,180.00 -1,749.50 -522.17 -793.67 0.00 -908.50 -710.60 -1,572.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 22.73 25.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.97 -0.96 -1.21 -1.06 -1.20 -2.25 -1.90 -2.48 -1.80 -3.93 -5.27
Invested Capital Turnover		 -0.23 -0.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.23 -1.15 -1.66 -0.86 -0.23 -1.29 -0.69 -1.43 -0.61 -1.69 -3.37
Enterprise Value (EV)		 -11 -6.83 -6.18 -6.78 -3.60 -7.55 -4.23 -1.84 2.83 217 158
Market Capitalization		 3.99 5.44 5.10 4.22 4.20 2.19 2.99 3.26 7.84 350 290
Book Value per Share		 $2.05 $1.23 $0.79 $10.61 $5.58 $5.63 $1.21 $0.55 $0.35 $0.87 $0.77
Tangible Book Value per Share		 $2.05 $1.23 $0.79 $10.61 $5.58 $5.63 $1.21 $0.55 $0.35 $0.87 $0.77
Total Capital		 14 11 10 10 6.84 7.57 5.33 2.93 3.42 129 127
Total Debt		 0.26 0.16 0.00 0.35 0.24 0.08 0.00 0.31 0.21 0.07 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -12 -11 -11 -7.81 -9.74 -7.23 -5.10 -5.02 -133 -133
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.44 -1.53 -1.73 -1.53 -1.62 -2.48 -2.12 -2.63 -1.67 -3.73 -5.01
Debt-free Net Working Capital (DFNWC)		 14 11 9.55 9.83 6.42 7.34 5.11 2.79 3.56 130 128
Net Working Capital (NWC)		 14 11 9.55 9.48 6.19 7.26 5.11 2.48 3.35 130 128
Net Nonoperating Expense (NNE)		 0.95 0.76 0.96 1.13 0.97 0.98 0.61 0.79 0.82 1.91 2.08
Net Nonoperating Obligations (NNO)		 -15 -12 -11 -11 -7.81 -9.74 -7.23 -5.10 -5.02 -133 -133
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -574.40% -612.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 5,550.40% 4,360.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 5,446.80% 4,296.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.35) ($97.80) ($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 489.62K 30.40K 768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M
Adjusted Diluted Earnings per Share		 ($7.35) ($97.80) ($4.59) ($3.32) ($2.32) $7.83 ($0.47) ($0.58) ($0.38) $0.14 ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 489.62K 30.40K 768.14K 1.23M 1.50M 1.42M 4.80M 4.80M 7.47M 55.67M 209.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($97.80) $0.00 $0.00 $0.00 $7.83 $0.00 $0.00 $0.00 $0.14 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 614.48K 851.40K 937.56K 1.18M 1.33M 4.40M 4.80M 9.12M 149.00M 165.88M 173.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.64 -2.21 -2.57 -2.95 -2.52 -2.37 -1.62 -1.99 -2.05 -6.99 -7.52
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -448.50 -741.75 -3,526.00 -2,039.00 -580.17 -1,113.67 0.00 -1,391.00 -572.60 -4,448.50 0.00
NOPAT to Interest Expense		 -330.58 -551.95 -2,571.10 -1,473.85 -419.18 -789.13 0.00 -995.05 -409.08 -3,493.35 0.00
EBIT Less CapEx to Interest Expense		 -448.50 -741.75 -3,526.00 -2,039.00 -580.17 -1,113.67 0.00 -1,391.00 -572.60 -4,448.50 0.00
NOPAT Less CapEx to Interest Expense		 -330.58 -551.95 -2,571.10 -1,473.85 -419.18 -789.13 0.00 -995.05 -409.08 -3,493.35 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -6.60% -5.02% -1.51% -3.20% -3.60% -3.99% -5.74% -3.09% -2.65% -3.68% -2.01%

Financials Breakdown Chart

Key Financial Trends

Palisade Bio’s latest quarter shows a company still in pre-revenue development mode, with no revenue and ongoing operating losses, but it also has a much stronger cash position than it did a year ago. The biggest takeaway is that the company raised substantial capital in late 2025, which lifted cash and equity sharply. At the same time, quarterly cash burn remains meaningful, and the share count has increased significantly over the past year.

  • Cash and equivalents rose to $132.6 million in Q1 2026, up dramatically from $5.2 million in Q3 2025 and $7.2 million in Q1 2025.
  • The balance sheet is currently very liquid, with $133.3 million in total assets versus only $6.0 million in total liabilities.
  • Debt is minimal, with no short-term debt reported in Q1 2026.
  • Q1 2026 financing activity added $3.25 million from common equity issuance, helping offset operating cash outflows.
  • Other income provided a modest boost in Q1 2026, with $1.15 million in net other income.
  • Palisade Bio continues to report no revenue, so the business remains dependent on financing and pipeline progress rather than commercial sales.
  • Operating expenses in Q1 2026 were $10.7 million, down from $10.0 million in Q4 2025 and well below some earlier quarters in 2024, but still substantial for a company with no revenue.
  • Research and development spending in Q1 2026 was $6.4 million, indicating the company is still investing in development programs.
  • The company’s equity base expanded sharply over the last year, reflecting capital raises and a much larger outstanding share count.
  • Q1 2026 net loss was $9.6 million, compared with a loss of $8.9 million in Q4 2025 and $2.9 million in Q3 2025.
  • Operating cash flow remained negative at -$3.9 million in Q1 2026, after -$3.1 million in Q4 2025 and -$3.6 million in Q3 2025.
  • The company reported a net cash outflow of $757,000 in Q1 2026 despite the financing raise.
  • Shares outstanding have increased sharply over time, which can dilute existing shareholders; Q1 2026 basic weighted average shares were 209.7 million, versus 7.5 million in Q3 2025 and 4.8 million in Q1 2025.
  • Retained earnings remain deeply negative at -$162.3 million, reflecting a long history of accumulated losses.

Trend summary: Over the last four years, Palisade Bio has consistently generated losses and negative operating cash flow, which is typical for a clinical-stage biotech. The notable change is on the financing side: the company successfully raised enough capital to end Q1 2026 with a large cash balance and a very strong near-term liquidity position. That lowers immediate financial distress risk, but it does not change the core issue that the business still has no revenue and continues to burn cash.

What investors may want to watch next: whether management can translate its cash runway into meaningful clinical or strategic progress, and whether operating losses start to narrow without additional heavy dilution.

07/14/26 02:42 AM ETAI Generated. May Contain Errors.

Palisade Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Palisade Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, Palisade Bio's net income has ranged from -$26.62 million in 2021 to -$4.92 million in 2018, and is currently -$16.78 million as of their latest financial filing in 2025. Check out Palisade Bio's forecast to explore projected trends and price targets.

Palisade Bio's total operating income in 2025 was -$18.06 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $18.06 million

Over the last 10 years, Palisade Bio's total revenue changed from $10.42 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

Palisade Bio's total liabilities were at $4.96 million at the end of 2025, a 46.5% increase from 2024, and a 50.3% decrease since 2015.

In the past 10 years, Palisade Bio's cash and equivalents has ranged from $713 thousand in 2020 to $133.39 million in 2025, and is currently $133.39 million as of their latest financial filing in 2025.

Over the last 10 years, Palisade Bio's book value per share changed from 0.05 in 2015 to 0.87 in 2025, a change of 1,505.0%.


Related Companies

Financial statements for NASDAQ:PALI last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Forget SpaceX, this is Elon’s Next Breakthrough
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel